Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 12.9% | - | - |
| 2024 |
|---|
| 16.6% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 12.9% | - | - |
| 2024 |
|---|
| 16.6% |
GreenWood delivered exceptional 2025 performance with 52.5% net returns versus 22.1% for MSCI ACWI, driven by solid fundamental execution and behavioral narrative improvements across portfolio companies. The firm's collaborative approach involves active board participation in nearly 80% of holdings, working directly with management teams to improve business quality and unlock catalysts. Key contributors included Leonardo's continued transformation, Genus achieving FDA approval for gene-editing technology, NexGen progressing toward uranium mine approval, and successful governance interventions at Jack in the Box. The portfolio maintains value orientation with significant upside potential as companies transition toward compounder status. GreenWood's behavioral framework anticipates investor perception shifts while emphasizing owner-operator alignment through meaningful insider ownership and board representation. Looking ahead, the firm remains bullish on long-term transformation prospects while maintaining focus on risk management and capital preservation. Multiple catalysts across the portfolio position for continued outperformance as companies execute on operational improvements and strategic milestones throughout 2026.
GreenWood generates alpha through collaborative ownership and governance improvements, applying behavioral framework to anticipate investor perception changes while working directly with management teams to unlock value through operational excellence and strategic catalysts.
Bullish on long-standing investments with focus on continuous progress. Believes all portfolio companies have a chance at achieving compounder status as they fulfill their missions. Committed to being in board rooms of many companies pushing to make demonstrable progress during 2026.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 28 2026 | 2025 Q4 | GNS.L, IPCO.TO, JACK, LDO.MI, NXE, ODET.PA, UHR.SW | activism, Behavioral, Collaboration, global, Governance, turnaround, value |
NXE IPCO CN GNS LN UHR SW JACK |
NexGen Energy progressed closer to federal approval for its world-class Arrow deposit and provided fantastic drill results from Patterson Corridor East. The company raised nearly… |
| Aug 8 2025 | 2025 Q2 | C7T GR, LDO IM, MEIP, UHR SW | active ownership, alignment, Governance, Ownership, value creation | UHR SW | The commentary highlights active ownership as a core driver of value creation through governance, strategy, and capital allocation improvements. Management emphasizes partnering with high-integrity leaders… |
| Jan 7 2025 | 2024 Q4 | C7T GR, LDO IM, TPL | - | - | - |
| Aug 6 2024 | 2024 Q2 | C7T GR, LDO IM, MEIP | - | - | - |
| Mar 2 2024 | 2023 Q4 | BOL FP, CTT SS, LDO IM, MEIP, NXE, PDD, RTO | - | - | - |
| Apr 8 2023 | 2023 Q2 | BOP GR, RH | - | - | - |
| Jun 27 2023 | 2023 Q1 | CTT AU, MEIP, SFOR LN, VRNO CN | - | - | - |
| Jul 12 2022 | 2022 Q3 | CTT AU | - | - | - |
| Aug 24 2022 | 2022 Q2 | CTT AU, LTRPA, RH | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
Gene TherapyThe manager remains convinced that gene therapies will effectively cure patients with chronic and deadly diseases despite setbacks. Prime Medicine's elegant gene editing function offers simpler and safer treatment options with less off-target activity than first-generation technologies like CRISPR. |
CRISPR Editing Safety Chronic Diseases |
LuxuryNew investment in Swatch represents exposure to luxury watch brands including Omega, Longines, Tissot, and others. The investment thesis is based on tangible assets including Swiss real estate and the potential for operating leverage when luxury demand recovers from current structural pressures. |
Watches Swiss Brands Premium Recovery | |
Oil SandsInternational Petroleum Company's Blackrod project is coming online later in 2026 ahead of schedule and under budget. The company has self-funded a major greenfield oil project while simultaneously buying back 10% of its available free float per year. |
Oil Energy Development Canada Production | |
RestaurantsSteak n Shake achieved industry-leading 10.2% same-store sales growth in 2025, marking the best performance since 1992. The company is transforming through premium quality ingredients including 100% beef tallow fries, cane sugar Coca-Cola, and plans for 100% grass-fed Steakburgers. The franchise partner program has converted 179 company-operated units to single-unit franchise partnerships, with franchise partners generating about 70% of store-level cash flows. |
Steak n Shake Franchise Quality Growth Transformation | |
UraniumDemand surging from nuclear restarts and new construction while supply faces operational challenges. Google, Meta partnerships signal corporate adoption of nuclear power. Sprott Physical Uranium Trust resumed buying 10 million pounds since June, helping drive 45% price increase. |
Nuclear SMR Utilities Physical | |
| 2025 Q2 |
Ownership |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 8, 2025 | Fund Letters | Steven Wood | UHR SW | The Swatch Group AG | Consumer Discretionary | Luxury Goods | Bull | Swiss Exchange | Brand Equity, Governance, Luxury, turnaround, Watches | Login |
| Jan 28, 2026 | Fund Letters | Steven Wood | NXE | NexGen Energy Ltd | Energy | Uranium | Bull | New York Stock Exchange | energy transition, Mining, Nuclear, Permitting, uranium | Login |
| Jan 28, 2026 | Fund Letters | Steven Wood | IPCO CN | International Petroleum Corp | Energy | Oil & Gas Exploration & Production | Bull | New York Stock Exchange | buybacks, capital allocation, NAV, oil, Oil sands | Login |
| Jan 28, 2026 | Fund Letters | Steven Wood | GNS LN | Genus plc | Health Care | Agricultural Biotechnology | Bull | New York Stock Exchange | Biotech, China, Gene Editing, Genetics, royalties | Login |
| Jan 28, 2026 | Fund Letters | Steven Wood | UHR SW | Swatch Group AG | Consumer Discretionary | Luxury Goods | Bull | Swiss Exchange | balance sheet, brands, Governance, Luxury, turnaround | Login |
| Jan 28, 2026 | Fund Letters | Steven Wood | JACK | Jack in the Box Inc. | Consumer Discretionary | Restaurants | Bull | NASDAQ | Activism, Governance, Real Estate, Restaurants, turnaround | Login |
| TICKER | COMMENTARY |
|---|---|
| GNS.L | Genus (GNS LN) Value GARP 48% FDA & China catalysts added significant value. Genus is a uniquely positioned animal genetics company that remains under-appreciated by the market, despite its 70% return during 2025 which led to Genus contributing nearly 3% to portfolio performance. The company's business is characterized by a highly recurring customer base, a royalty-like revenue stream, is relatively asset lite, and has dominant market share. |
| IPCO.TO | While International Petroleum Company's (IPCO) operating income declined in line with oil prices remaining under pressure during 2025, the primary driver of value for the company is the successful development of its Canadian oil sands project, Blackrod. The owner-operator management team has executed this project well, and Blackrod is coming online later in 2026 — ahead of schedule and under budget. |
| JACK | JACK is a top 20 restaurant brand by sales that had seen its stock fall on hard times since its all-time highs in 2021. We started our engagement with the company towards the end of 2024 as we saw a brand that had strong mindshare, but was being heavily weighed down by the Street's perception of debt concerns, prior capital allocation decisions, its geographic over-index to California, and significant executive turnover. |
| LDO.MI | Leonardo (LDO IM) GARP Compounder 77% Remains below peer average multiple. Added during risk-off moments, outperforming. Beyond the companies that we've already discussed, the rest of the portfolio is still anchored by CTT and Leonardo. While we are in quiet periods on both companies, the theses remain unchanged, and the commentary we provided in August of 2025 remains valid and on track. |
| NXE | NexGen Energy (NXE) which is a pre-production uranium company that is on the cusp of receiving federal approval for full scale development of its world-class Arrow deposit. NexGen added 4% to our net returns as it progressed closer to a federally approved project. Additionally, it provided fantastic drill results from another deposit (Patterson Corridor East, just 3.5km from Arrow), and continued to benefit from the supportive nuclear narrative spreading globally. |
| ODET.PA | Odet (ODET FP) Value Turnaround -30% Lack of buyback in 2H widened discount |
| UHR.SW | We made one new purchase in the quarter Swatch. Swatch offers a rare investment opportunity backed by both tangible and intangible assets, with a valuation that assumes very little goes right. Swatch's balance sheet includes net cash of approximately CHF 1.5bn and Swiss real estate with an estimated market value of around CHF 4bn. At today's market capitalisation, this implies a valuation of roughly 1x sales for Omega, one of the world's most recognisable luxury watch brands, while the remainder of the group's portfolio, including Longines, Tissot, Blancpain, Harry Winston, Swatch, and its extensive component manufacturing operations, effectively being valued at zero. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||